Chiesi Group struck an exclusive collaboration and license with Arbor Biotechnologies to develop ABO‑101, an in‑vivo CRISPR gene‑editing candidate for primary hyperoxaluria type 1 (PH1), in a deal that could total more than $2.1 billion. The agreement includes development and global commercialization rights for ABO‑101 and an option for additional liver‑directed gene editing programs. ABO‑101 uses lipid nanoparticles to deliver an mRNA‑encoded Cas12i2 nuclease designed to knock out HAO1 in hepatocytes to reduce oxalate production. The pact marks Chiesi’s first push into gene editing and gives the Italian rare‑disease builder access to Arbor’s platform and future options against other liver targets. The companies will continue the ongoing Phase I/II redePHine trial (NCT06839235) evaluating safety, tolerability and pharmacodynamics of ABO‑101. For developers and investors, the deal signals continued industry appetite for one‑time in‑vivo editing programs and confirms LNP‑delivered CRISPR modalities remain a commercial priority.